Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Nephros is a commercial stage company that develops and sells high performance wat...
Nephros is a commercial stage company that deve...
GluCase is an all-in-one diabetes management system that seamlessly integrates a g...
GluCase is an all-in-one diabetes management sy...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
We are an innovative clinical-stage biopharmaceutical company primarily focused on...
We are an innovative clinical-stage biopharmace...
ProPhase Labs is a diversified medical science and technology company. We develop,...
ProPhase Labs is a diversified medical science ...
We are a clinical-stage biopharmaceutical company focused on improving the lives o...
We are a clinical-stage biopharmaceutical compa...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Join the National Investor Network and get the latest information with your interests in mind.